Compared with conventional GC therapies such as surgery, chemotherapy, targeted therapy, or single‐agent immunotherapy, our iRGD NPs@si‐SOX9/CL platform integrates siRNA nanodelivery and PDT to specifically suppress the SOX9/TIMP1/FAK/PI3K axis while simultaneously enhancing DC function. The gene discussed is PTK2; the disease is gastric cancer.